Group 1 - The controlling shareholder, China Baoan, holds a total of 126 million shares in the company, accounting for 29.27% of the total share capital [1] - A total of 10 million shares have been released from pledge, resulting in China Baoan having 90 million pledged shares, which represents 71.34% of its total holdings in the company and 20.88% of the company's total share capital [1] - The release of the pledge is effective from May 28, 2025 [1]

Core Viewpoint - The company plans to hold a performance briefing on June 6, 2025, to discuss its 2024 annual report and the first quarter report of 2025, allowing investors to engage and ask questions [2][3]. Group 1: Meeting Details - The performance briefing is scheduled for June 6, 2025, from 10:30 AM to 11:30 AM [4]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted via video live streaming and online interaction [4]. - Investors can submit questions from May 29, 2025, to June 5, 2025, before 4:00 PM through the Roadshow Center website or via the company's email [2][5]. Group 2: Participants - Key participants in the meeting include Chairman Chen Ping, General Manager Xia Youzhang, and other senior executives [4]. Group 3: Investor Participation - Investors can join the performance briefing online on June 6, 2025, and the company will address commonly asked questions during the session [5]. - After the briefing, investors can access the meeting's details and main content through the Roadshow Center [5].

Core Viewpoint - The company, Mayinglong Pharmaceutical Group Co., Ltd., is set to hold a performance briefing on June 6, 2025, to discuss its 2024 annual results and Q1 2025 performance, allowing for investor interaction and questions [1][2]. Group 1: Meeting Details - The performance briefing is scheduled for June 6, 2025, from 10:30 AM to 11:30 AM [2][3]. - The meeting will take place at the Shanghai Stock Exchange Roadshow Center, accessible via the website: https://roadshow.sseinfo.com/ [2][3]. - The format of the meeting will be a combination of video and online interaction, enabling real-time communication with investors [2][3]. Group 2: Participation Information - Investors can submit questions from May 29, 2025, to June 5, 2025, by visiting the "Pre-Question Collection" section on the Shanghai Stock Exchange Roadshow Center website or by emailing ir@mayinglong.cn [3]. - During the briefing, the company will address commonly asked questions from investors within the scope of information disclosure [2][3]. Group 3: Key Personnel - Key participants in the meeting will include Chairman Chen Ping, General Manager Xia Youzhang, Secretary of the Board Ma Qian, CFO Mao Tao, and Independent Director Mao Peng [2].

证券代码：600993 证券简称：马应龙 公告编号：临 2025-008 马应龙药业集团股份有限公司 关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 5 月 29 日(星期四)至 6 月 5 日(星期四)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@mayinglong.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 马应龙药业集团股份有限公司（以下简称"公司"）已于 2025 年 4 月 3 日发 布了公司 2024 年年度报告、2025 年 4 月 26 日发布了公司 2025 年第一季度报告， 为便于广大投资者更全面深入地了解公司 2024 年度、2025 年第一季度经营成果、 财务状况，公司计划于 2025 年 6 月 6 日（星期五）上午 10:30-11:30 举行 2024 年 度暨 2025 年第一季度业绩说明会，就投资者关心的问题进行交流。 一、 ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has a strong foothold in the hemorrhoid treatment market, with a stable patient base and significant growth potential due to the high prevalence of hemorrhoid diseases, which affects over 50% of the population. The overall annual growth rate for hemorrhoid medications is around 7% [7] - The company is expanding its product line into health and wellness sectors, particularly with eye creams and wet wipes, which are gaining traction in the market. The wet wipes segment is experiencing rapid growth, and the company holds competitive advantages in brand and product quality [8] - The company has implemented channel optimization strategies to enhance operational capabilities, focusing on expanding into county-level and lower-tier markets [8] Summary by Sections 1. Hemorrhoid Treatment Market Leadership - The company has over 400 years of history and a unique "Eight Treasure" formula that is recognized as a national intangible cultural heritage, providing a strong efficacy foundation for its products [11] - The company’s product portfolio includes a comprehensive range of hemorrhoid treatments, with a significant market share of 50% in retail sales [7][18] - The company’s pharmaceutical segment contributes 90% of its gross profit, indicating a robust revenue model [39] 2. Growth Potential in Health and Wellness - The company has launched products like the "Little Blue Wet Wipes," which have quickly gained popularity, ranking high on sales charts [28] - The health and wellness segment is expected to enhance brand recognition, especially among younger consumers, thereby increasing the penetration of OTC products [25] 3. Revenue and Profitability Forecast - Projected revenues for 2025-2027 are estimated at 4.346 billion, 5.025 billion, and 5.822 billion yuan, respectively, with net profits expected to be 624 million, 742 million, and 890 million yuan, corresponding to PE ratios of 18.59, 15.64, and 13.04 times [8]

Group 1 - The company achieved an operating revenue of 969 million in the first quarter of 2025, representing a year-on-year growth of 1.48% [1] - The net profit for the same period was 204 million, showing a year-on-year increase of 2.99% [1]

Financial Performance - The company's operating revenue for Q1 2025 was CNY 969,147,449.22, representing a year-on-year increase of 1.48% compared to CNY 955,017,184.55 in the same period last year[3]. - The net profit attributable to shareholders of the listed company reached CNY 203,572,140.06, reflecting a growth of 2.99% from CNY 197,665,895.38 in the previous year[3]. - The basic earnings per share rose to CNY 0.47, up 2.17% from CNY 0.46 in the previous year[3]. - Total operating revenue for Q1 2025 reached ¥969,147,449.22, a slight increase of 1.2% compared to ¥955,017,184.55 in Q1 2024[16]. - Net profit for Q1 2025 was ¥210,010,562.64, representing a 3.9% increase from ¥203,220,964.27 in Q1 2024[17]. - Earnings per share for Q1 2025 was ¥0.47, compared to ¥0.46 in Q1 2024[17]. - The total comprehensive income for the first quarter of 2025 was CNY 198,904,563.66, compared to CNY 207,780,747.12 in the first quarter of 2024, reflecting a decrease of approximately 4.2%[28]. - Basic and diluted earnings per share for the first quarter of 2025 were both CNY 0.46, down from CNY 0.48 in the same period last year, indicating a decline of about 4.2%[28]. Cash Flow - The net cash flow from operating activities significantly increased by 157.85%, amounting to CNY 153,332,989.59, compared to CNY 59,465,024.89 in the same period last year[3]. - The company reported a significant increase in cash flow due to higher interest income from time deposits and the issuance of payable notes for goods procurement[6]. - Cash inflows from operating activities totaled CNY 1,091,010,262.77 in Q1 2025, an increase of approximately 18.8% from CNY 918,254,814.69 in Q1 2024[30]. - Net cash flow from operating activities was CNY 649,393,018.82, compared to CNY 457,172,228.65 in the previous year, representing a growth of around 42.1%[30]. - Cash inflows from operating activities included CNY 382,636,583.55 from sales of goods and services, a decrease from CNY 428,778,352.18 in the previous year[30]. - Cash received from other operating activities increased to CNY 708,373,679.22, up from CNY 489,476,462.51, marking a growth of approximately 44.8%[30]. - The company's cash flow from investment activities showed a net outflow of approximately ¥1.32 billion, compared to a net outflow of about ¥629 million in the previous period, indicating a significant increase in investment expenditures[21]. - The cash flow from financing activities showed a net outflow of approximately ¥31.66 million, compared to a net outflow of about ¥10.52 million in the previous period, suggesting increased financial strain[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,447,625,927.72, an increase of 5.13% from CNY 5,181,936,729.77 at the end of the previous year[3]. - The equity attributable to shareholders of the listed company was CNY 4,269,485,832.69, reflecting a growth of 5.01% from CNY 4,065,961,926.61 at the end of the previous year[3]. - The company's total liabilities increased to RMB 1,726,457,309.30 from RMB 1,610,608,262.94, representing a rise of approximately 7.19%[13]. - Total current liabilities increased to RMB 863,128,369.65 from RMB 804,356,681.07, marking a rise of about 7.27%[13]. - The total assets of the company as of March 31, 2025, were approximately ¥5.66 billion, an increase from ¥4.74 billion at the end of 2024, reflecting growth in asset base[24]. - The company's total liabilities increased to approximately ¥1.21 billion from ¥485 million, indicating a significant rise in financial obligations[24]. Investments and Expenses - Research and development expenses for Q1 2025 were ¥18,835,159.65, an increase of 12.2% from ¥16,788,255.40 in Q1 2024[16]. - Research and development expenses increased to approximately ¥15.74 million in the first quarter of 2025, up from ¥13.50 million in the first quarter of 2024, indicating a focus on innovation[27]. - Cash outflows from investing activities amounted to CNY 1,633,455,524.90, significantly higher than CNY 698,790,626.25 in Q1 2024, indicating an increase of approximately 133.4%[30]. - The net cash flow from investing activities was -CNY 1,272,074,464.65, worsening from -CNY 569,320,881.27 year-over-year[30]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,455[7]. - Total equity attributable to shareholders reached ¥4,269,485,832.69, up from ¥4,065,961,926.61 in Q1 2024[14]. - The company's total equity increased to approximately ¥4.45 billion from ¥4.25 billion, indicating a strengthening of the shareholders' equity position[25].

Core Insights - The article highlights the growing trend of pharmaceutical companies entering the beauty and skincare market, with notable examples such as Mayinglong and its 30% year-on-year revenue growth in its beauty product line for 2024 [1] - The competitive landscape is evolving, with some pharmaceutical brands successfully establishing themselves in the beauty sector, while others struggle to maintain profitability and market presence [2][3] Group 1: Pharmaceutical Companies Entering Beauty Market - Mayinglong reported a significant revenue increase in its beauty product line, indicating a successful cross-industry expansion [1] - Other pharmaceutical companies like Yunnan Baiyao and Pianzaihuang have also ventured into beauty, but face challenges such as market saturation and declining revenue in their beauty segments [5][6] - The trend of "dimensionality reduction" is noted, where pharmaceutical companies leverage their research and development strengths to compete in the beauty market [2][3] Group 2: Challenges and Market Dynamics - Many pharmaceutical companies are experiencing difficulties in the beauty market due to product homogeneity and a lack of innovative marketing strategies [6][7] - The shift towards scalp care products is emerging as a new opportunity, with companies like Yunnan Baiyao reporting significant revenue growth in this area [9] - The scalp care market is projected to grow, with pharmaceutical companies aiming to differentiate their products through unique formulations and proprietary ingredients [9]

Core Insights - The company, Mayinglong Pharmaceutical Group Co., Ltd., reported a record high net profit of 528 million yuan for 2024, marking a year-on-year growth of 19.14% [1] - The company attributes its performance to a combination of digital intelligence, green practices, and innovation, which it refers to as "new quality productivity" [5] Digital Transformation - Mayinglong is implementing digital innovations across its entire supply chain, achieving 100% digital management of core production lines and utilizing digital twin technology for real-time production monitoring [2] - The company has introduced automated guided vehicles (AGVs) for product transport, enhancing logistics efficiency while reducing energy consumption [2] - The establishment of a comprehensive digital marketing system has improved consumer engagement through various channels, including short videos and live streaming [2] Green Practices - The company integrates ESG principles into its operations, actively pursuing energy-saving and carbon-reduction initiatives in response to national dual carbon policies [3] - Investments in advanced green production lines and environmental management systems have led to significant reductions in energy consumption and emissions [3] - Mayinglong has been recognized as a "National Green Factory" and a green manufacturing demonstration enterprise in Hubei province [3] AI and Innovation - Mayinglong has developed an intelligent manufacturing cloud platform that connects data from suppliers and customers, enhancing coordination across production, supply, and sales [4] - The company focuses on strategic areas such as proctology, ophthalmology, and dermatology, with significant advancements in product development, including several new drug registrations [4] - In 2024, the company invested 66.69 million yuan in R&D, successfully completing the development of 60 health products across various sectors [4]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% against the market benchmark within the next six months [4][18]. Core Insights - The company reported a revenue of 3.73 billion (up 18.9% year-on-year) and a net profit of 530 million (up 19.1% year-on-year) for 2024, with a significant increase in non-recurring net profit by 45% [1][4]. - The fourth quarter of 2024 saw a revenue of 940 million (up 35.6% year-on-year) and a net profit of 70.59 million (up 183.8% year-on-year) [1][4]. - The adjustments in the pharmaceutical channel have shown effectiveness, with the pharmaceutical industry segment achieving a revenue of 2.16 billion (up 17.8% year-on-year) and a gross margin of 71.4% [2][3]. Revenue Breakdown - The company's revenue from hemorrhoid treatment products reached 1.59 billion (up 23.2% year-on-year) with a gross margin of 74% [3]. - The medical commercial segment generated 1.25 billion (up 14.8% year-on-year) with a gross margin of 8.7% [2]. - The healthcare services segment achieved a revenue of 450 million (up 30.2% year-on-year) [2]. Product Development - The company has made progress in multiple research projects, including obtaining clinical approval for a new hemorrhoid treatment and registration for eye care medications [3]. - A total of 60 health products have been developed, covering various categories such as cosmetics and medical devices, laying a solid foundation for future market expansion in the health sector [3]. Financial Forecast - The revenue projections for 2025, 2026, and 2027 are 4.21 billion, 4.73 billion, and 5.27 billion respectively, with growth rates of 13%, 12%, and 11% [4]. - Net profit forecasts for the same years are 680 million, 760 million, and 840 million, with growth rates of 29%, 12%, and 10% [4].